Tulmimetostat

CAS No. 2567686-02-4

Tulmimetostat( —— )

Catalog No. M35187 CAS No. 2567686-02-4

Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 60 In Stock
10MG 93 In Stock
25MG 183 In Stock
50MG 269 In Stock
100MG 532 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tulmimetostat
  • Note
    Research use only, not for human use.
  • Brief Description
    Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.
  • Description
    Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor. Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Histone Methyltransferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2567686-02-4
  • Formula Weight
    562.12
  • Molecular Formula
    C28H36ClN3O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC1=C2C(O[C@@](C)(O2)[C@@]3(CC[C@H](CC3)N4CC(OC)C4)[H])=C(Cl)C=C1C(NCC5=C(SC)C=C(C)NC5=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.
molnova catalog
related products
  • CPI-1189

    REN-1189 is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.

  • CCP peptide TFA

    CCP peptide TFA is a synthetic cyclocitrullinated peptide (CCP) that ACTS as a serum substrate for the detection of anti-ccp antibodies.

  • Elotuzumab

    Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.